For patients with inherited bleeding disorders, the goal of treatment is not a cure, but a stable, predictable life. The standard of care often involves frequent, burdensome infusions of clotting factor proteins. A Vancouver-based biotech, SeraGene Therapeutics, is betting that a monthly injection of RNA, delivered to the liver, can offer a more durable and potentially safer prophylactic option [NBDF, Feb 2026].
The RNA wedge into coagulation
SeraGene's approach leverages lipid nanoparticles (LNPs) to direct small interfering RNA (siRNA) to liver cells to precisely modulate the production of proteins involved in blood clotting [Perplexity Sonar Pro Brief]. The lead program, SG-001, aims to be a universal prophylactic agent for rare bleeding disorders by suppressing plasminogen to stabilize a patient's own hemostatic system [Perplexity Sonar Pro Brief].
A portfolio built on academic roots
The company, founded in 2022, is a spinout from the Nanomedicines Innovation Network (NMIN) and the Versiti Blood Research Institute [Perplexity Sonar Pro Brief]. CEO Dr. Erika Siren leads the company, which has progressed eight patented assets from discovery to late preclinical stages [NMIN, Oct 2024].
The validation of a strategic investor
In late 2025, SeraGene secured a strategic seed investment from Pathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation (NBDF) [BusinessWire, Nov 2025]. The fund was joined by Hextwo Capital, which has supported the company's acceleration through programs like Creative Destruction Lab and adMare BioInnovations [adMare BioInnovations].
| Investor | Type | Notable Focus |
|---|---|---|
| Pathway to Cures | Venture Philanthropy | Fund of the National Bleeding Disorders Foundation (NBDF) |
| Hextwo Capital | Venture Capital | Early-stage life sciences |
Navigating the long road to clinic
SeraGene remains in the preclinical phase. The company's technology must prove its safety and efficacy in humans, a process that will require significant capital and time. Key milestones to watch include the publication of robust preclinical data, the securing of a Series A round, and any strategic partnership with an established player in the hematology space.